Drug Trial Radar · NCT07359963
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Feb 15, 2026
Primary completion
Feb 15, 2027
Study completion Jun 15, 2027
Sponsor
- Lead sponsor
- Regend TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
REGEND007 Cell TherapyBiological
This study's intravenous infusion dose escalation protocol is based on a 3+3 dose escalation design, with a total of 4 dose groups. Each group included 3 subjects, and the dose is gradually increased until the maximum tolerated dose(MTD) or the maximum administered dose (MAD) is reached.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of drug-related adverse events (AEs)Time frame: 12 weeks after the administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fourth Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.